Show simple item record

CEREBRAL CRYPTOCOCOSIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. CASE REPORT

Criptococosis cerebral, voriconazol, niveles plasmáticos y síndrome de reconstitución inmune. Reporte de un caso

dc.contributoren-US
dc.contributores-ES
dc.creatorTéllez R, María; Universidad Austral de Chile
dc.creatorSalgueiro C, Catalina; Universidad Austral de Chile
dc.creatorLeiva Hernández, Marcelo; Hospital Base de Valdivia
dc.creatorFica, Alberto; Hospital Base de Valdivia
dc.date2018-11-12
dc.date.accessioned2019-11-11T18:26:48Z
dc.date.available2019-11-11T18:26:48Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6929
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110839
dc.descriptionWe report a 45 years old male with AIDS who had a Cryptococcus neoformans central nervous system infection. He was treated with amphotericin B deoxycolate subsequently changed to voriconazole due to systemic toxicity of the former. Plasma voriconazole trough levels were insufficient with a standard dose (0.7 µg/mL); therefore, the dose was increased thereafter to reach appropriate levels (4.5 µg/mL). Anti-retroviral therapy was started five weeks after voriconazole initiation with non-interacting drugs and he was discharged after a favorable evolution. He was re-admitted three months later due to seizures; a brain magnetic resonance showed new sub-cortical nodules. After excluding alternative causes and demonstrating fungal eradication, an immune reconstitution inflammatory syndrome (IRIS) event was suspected and treated with a short course of steroids. His evolution was satisfactory.en-US
dc.descriptionWe report a 45 years old male with AIDS who had a Cryptococcus neoformans central nervous system infection. He was treated with amphotericin B deoxycolate subsequently changed to voriconazole due to systemic toxicity of the former. Plasma voriconazole trough levels were insufficient with a standard dose (0.7 µg/mL); therefore, the dose was increased thereafter to reach appropriate levels (4.5 µg/mL). Anti-retroviral therapy was started five weeks after voriconazole initiation with non-interacting drugs and he was discharged after a favorable evolution. He was re-admitted three months later due to seizures; a brain magnetic resonance showed new sub-cortical nodules. After excluding alternative causes and demonstrating fungal eradication, an immune reconstitution inflammatory syndrome (IRIS) event was suspected and treated with a short course of steroids. His evolution was satisfactory.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6929/4544
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36294
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36295
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36296
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36297
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36298
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36299
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36300
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36301
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36360
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/36630
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/37580
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6929/37581
dc.sourceRevista Médica de Chile; Vol. 146, núm. 12 (2018): DICIEMBRE 2018es-ES
dc.source0034-9887
dc.subjectAcquired Immunodeficiency Syndrome; Drug monitoring; Immune Reconstitution Inflammatory Syndrome; Meningitis Cryptococcal; Voriconazoleen-US
dc.subjectAcquired Immunodeficiency Syndrome; Drug monitoring; Immune Reconstitution Inflammatory Syndrome; Meningitis Cryptococcal; Voriconazolees-ES
dc.titleCEREBRAL CRYPTOCOCOSIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. CASE REPORTen-US
dc.titleCriptococosis cerebral, voriconazol, niveles plasmáticos y síndrome de reconstitución inmune. Reporte de un casoes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record